Apr. 3 at 10:59 AM
Biotech just keeps leveling up in psoriasis
👉Click to view @NasdaqPulse for timely updates amid the volatility.
Millions of patients are impacted globally, and the race is on to deliver better, faster, and more targeted solutions. The shift toward precision therapies is changing the game — higher efficacy, fewer side effects, and improved patient convenience.
Big pharma isn’t sitting this one out.
$ABBV and
$JNJ are pushing forward with next-gen psoriasis treatments, doubling down on targeted biologics and innovation pipelines that could redefine standards of care.
This space isn’t just medical — it’s a multi-billion dollar opportunity with long-term demand.
Watch for clinical data, approvals, and pipeline updates… this trend is only getting stronger.
